Abstract |
Coherence therapy, popularly known by the acronym ADFR (Activate, Depress, Free, Repeat), was designed to increase bone mass in osteopenic patients. Accordingly, we report a case of a hypogonadal male with histologically proven low bone turnover osteoporosis and a progressive vertebral fracture syndrome, who responded favorably to ADFR treatment with the use of salmon calcitonin and inorganic phosphate. Dramatic increments in bone mass were observed during a 68-month period of therapy. Serial quantitative computerized tomography demonstrated a 146% increase from baseline in bone mineral density for the first 30 months of treatment, and dual energy radiography yielded a 36.5% increase for the subsequent 31-68 months. Furthermore, no episode of fracture occurred since coherence therapy was initiated.
|
Authors | R C Armamento-Villareal, L V Avioli |
Journal | Calcified tissue international
(Calcif Tissue Int)
Vol. 51
Issue 4
Pg. 282-4
(Oct 1992)
ISSN: 0171-967X [Print] United States |
PMID | 1422973
(Publication Type: Case Reports, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Phosphates
- salmon calcitonin
- Reserpine
- Calcitonin
|
Topics |
- Adult
- Bone Density
(drug effects)
- Calcitonin
(therapeutic use)
- Drug Therapy, Combination
- Humans
- Male
- Osteoporosis
(chemically induced, drug therapy)
- Phosphates
(therapeutic use)
- Reserpine
(adverse effects)
- Spinal Diseases
(chemically induced, drug therapy)
|